Tokyo Tape
Sign in
← Sakai Chemical Industry

Half-year report · Q2

4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed

Amended by S100V7D8 (2025-02-07).

Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥41.9bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥82.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥2.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥2.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥3.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥2.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥121.2bnat 2024-09-30Cons.Assets
Total assets¥125.4bnat 2024-03-31Cons.Assets
Total assets¥131.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥44.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥50.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥77.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥75.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥14.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥16.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥14.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥7.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.712024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-437.652023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥97.232024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio59.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.2bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2024-04-01 → 2024-09-30¥38.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2024-04-01 → 2024-09-30¥37.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥798m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2024-04-01 → 2024-09-30¥4.4bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2024-04-01 → 2024-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥111m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2024-04-01 → 2024-09-30¥65m
—segment totalrevenue2024-04-01 → 2024-09-30¥42.8bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥41.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥910m
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 516
ItemContextValueUnit
Independent auditors report consolidated (text)FilingDateInstantText · Plus
Audit firm1 consolidatedFilingDateInstant
Original text (Japanese)有限責任　あずさ監査法人
Cpa1 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)三宅　　潔
Cpa2 audit firm1 consolidatedFilingDateInstant
Original text (Japanese)福島　康生
Number of submissionFilingDateInstant1
Net sales (5-year summary)Prior1YTDDuration40471000000JPY
Net sales (5-year summary)CurrentYTDDuration41874000000JPY
Net sales (5-year summary)Prior1YearDuration82105000000JPY
Ordinary income loss (5-year summary)Prior1YTDDuration885000000JPY
Ordinary income loss (5-year summary)CurrentYTDDuration2633000000JPY
Ordinary income loss (5-year summary)Prior1YearDuration3066000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YTDDuration-2033000000JPY
Profit loss attributable to owners of parent (5-year summary)CurrentYTDDuration1746000000JPY
Profit loss attributable to owners of parent (5-year summary)Prior1YearDuration-7092000000JPY
Comprehensive income (5-year summary)Prior1YTDDuration-542000000JPY
Comprehensive income (5-year summary)CurrentYTDDuration2383000000JPY
Comprehensive income (5-year summary)Prior1YearDuration-5164000000JPY
Net assets (5-year summary)Prior1QuarterInstant80656000000JPY
Net assets (5-year summary)CurrentQuarterInstant77140000000JPY
Net assets (5-year summary)Prior1YearInstant75466000000JPY
Total assets (5-year summary)Prior1QuarterInstant131575000000JPY
Total assets (5-year summary)CurrentQuarterInstant121246000000JPY
Total assets (5-year summary)Prior1YearInstant125445000000JPY
Basic earnings loss per share (5-year summary)Prior1YTDDuration-125.53
Basic earnings loss per share (5-year summary)CurrentYTDDuration107.71
Basic earnings loss per share (5-year summary)Prior1YearDuration-437.65
Diluted earnings per share (5-year summary)Prior1YTDDuration－
Diluted earnings per share (5-year summary)CurrentYTDDuration97.23
Diluted earnings per share (5-year summary)Prior1YearDuration－
Equity to asset ratio (5-year summary)Prior1QuarterInstant0.605
Equity to asset ratio (5-year summary)CurrentQuarterInstant0.627
Equity to asset ratio (5-year summary)Prior1YearInstant0.593
Net cash provided by used in operating activities (5-year summary)Prior1YTDDuration3187000000JPY
Net cash provided by used in operating activities (5-year summary)CurrentYTDDuration7420000000JPY
Net cash provided by used in operating activities (5-year summary)Prior1YearDuration6866000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YTDDuration-1625000000JPY
Net cash provided by used in investing activities (5-year summary)CurrentYTDDuration-2952000000JPY
Net cash provided by used in investing activities (5-year summary)Prior1YearDuration-3963000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YTDDuration1587000000JPY
Net cash provided by used in financing activities (5-year summary)CurrentYTDDuration-6578000000JPY
Net cash provided by used in financing activities (5-year summary)Prior1YearDuration1259000000JPY
Cash and cash equivalents (5-year summary)Prior1QuarterInstant15524000000JPY
Cash and cash equivalents (5-year summary)CurrentQuarterInstant14633000000JPY
Cash and cash equivalents (5-year summary)Prior1YearInstant16475000000JPY
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember17000000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant_OrdinaryShareMember17000000
Number of issued shares as of fiscal year end issued shares total number of shares etcFilingDateInstant17000000
Number of issued shares as of filing date issued shares total number of shares etcFilingDateInstant17000000
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember2401000
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.1481

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass